id: hepatitis_c_treatment_completion_to_kidney_disease
name: HCV Treatment with Direct-Acting Antivirals â†’ Chronic Kidney Disease Progression
from_node:
  node_id: hepatitis_c_treatment_completion
  node_name: HCV Treatment with Direct-Acting Antivirals
to_node:
  node_id: kidney_disease
  node_name: Chronic Kidney Disease Progression
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Patients with chronic kidney disease (CKD) receive direct-acting antiviral
  (DAA) therapy for hepatitis C virus (HCV) infection, achieving viral eradication
  rates greater than 95%'
- 'Step 2: Successful HCV treatment eliminates ongoing viral-mediated inflammatory
  processes and immune complex deposition that contribute to glomerulonephritis and
  other HCV-associated kidney diseases'
- 'Step 3: Eradication of HCV infection removes the independent risk factor for faster
  CKD progression, resulting in slower decline in glomerular filtration rate (GFR)
  after treatment compared to before treatment'
- 'Step 4: Reduced kidney inflammation and improved metabolic parameters slow the
  progression of chronic kidney disease toward end-stage renal disease'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'C. Gordon et al. 2019. Prevention, Diagnosis, Evaluation, and
    Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of
    the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline.
    Annals of Internal Medicine.'
  supporting_citations: []
description: Direct-acting antiviral treatment for hepatitis C virus achieves viral
  eradication in over 95% of patients with chronic kidney disease. HCV infection has
  been identified as an independent risk factor for faster CKD progression, related
  in part to HCV-associated glomerulonephritides but also independent of this connection.
  Studies show that successful HCV treatment results in slower decline in glomerular
  filtration rate after treatment compared to before treatment in patients with eGFR
  less than 60 mL/min/1.73m2, suggesting that viral eradication slows CKD progression.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 0.95
    type: viral_eradication_rate
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: null
moderators:
- name: CKD Stage
  direction: strengthens
  strength: moderate
  description: Patients with estimated GFR less than 60 mL/min/1.73m2 showed slower
    decrease in GFR after successful HCV treatment compared to before treatment
- name: HCV-associated glomerulonephritis
  direction: strengthens
  strength: strong
  description: HCV infection is associated with several glomerulonephritides; treatment
    of underlying HCV may provide greater benefit in these cases
- name: Dialysis modality
  direction: weakens
  strength: weak
  description: Patients on hemodialysis have higher HCV prevalence due to nosocomial
    transmission risks, potentially complicating treatment benefits
